These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 3103772

  • 21. [The effect of temocapril, an angiotensin-converting enzyme inhibitor with preferential biliary excretion, on experimental diabetic nephropathy].
    Yanagisawa Y.
    Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1095-102. PubMed ID: 7815741
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy.
    Ranganathan S, Krempf M, Feraille E, Charbonnel B.
    Diabete Metab; 1993 Oct; 19(2):257-61. PubMed ID: 8339858
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Telmisartan vs. enalapril in type 2 diabetes.
    Loewenstein JE.
    N Engl J Med; 2005 Feb 24; 352(8):835-6; author reply 835-6. PubMed ID: 15736291
    [No Abstract] [Full Text] [Related]

  • 27. [Effect of angioprotectors on the glomerular filtration rate and vascular permeability in diabetic angiopathies].
    Tirkina TN, Mirkhodzhaev AKh, Alekseev IuP, Ionushas BS, Kasymova SD.
    Probl Endokrinol (Mosk); 1979 Feb 24; 25(4):11-6. PubMed ID: 471968
    [Abstract] [Full Text] [Related]

  • 28. Telmisartan vs. enalapril in type 2 diabetes.
    Parving HH, Hovind P, Rossing P.
    N Engl J Med; 2005 Feb 24; 352(8):835-6; author reply 835-6. PubMed ID: 15736292
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ, Chiew Y, Ahmad B, Kadir KA.
    Nutrients; 2018 Sep 17; 10(9):. PubMed ID: 30227659
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I, Degrell P, Komáromy A, Molnár GA, Wagner Z, Wagner L, Mazák I, Nagy J.
    Orv Hetil; 2003 Mar 30; 144(13):613-9. PubMed ID: 12728786
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Anti-platelet therapy in diabetic and non-diabetic progressive renal failure.
    Gordge MP, Rylance PB, Neild GH.
    Clin Nephrol; 1992 Jan 30; 37(1):53-5. PubMed ID: 1541067
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.